Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab, Sirolimus, or Daclizumab for AMD
NCT00304954Phase 2Completed
- Sponsor
- National Eye Institute
- Start
- Feb 2006
- Primary completion
- Jan 2010
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daclizumab, infliximab and nab-sirolimus in age-related macular degeneration (AMD) and choroidal neovascularization (CNV), sponsored by National Eye Institute. Started Feb 2006; status: completed.
02
Drugs
daclizumabinfliximabnab-sirolimus
03
Conditions
age-related macular degeneration (AMD)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00304954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304954.